H1 (Interim)
ADAG — H1 2026 Financial Report Analysis
Adagene's H1 2026 net loss widened 21.5% to $16.4M, mostly on FX and warrant revaluation, while an April share sale lifted cash to $127.9M and runway into late 2028, past its 1H 2027 Phase 2 colorectal-cancer readout.